Piper Sandler Cuts Natera Price Target to $70.00
June 22, 2023
🌧️Trending News
Natera ($NASDAQ:NTRA) is a biotechnology company based in San Carlos, California that specializes in genetic testing. The company’s core technology platform provides screening, diagnostic, and monitoring tests to detect genetic abnormalities in embryos, and other tests for reproductive health and cancer. Recently, analysts at Piper Sandler have reduced the price target of Natera to $70.00, as reported by Defense World. This has caused a decline in Natera’s stock value on the market.
The revised price target from Piper Sandler is based on their expectations of the company’s future performance in the face of challenging market conditions. Overall, Natera remains a strong player in the biotechnology sector and investors should keep an eye on their performance as the market uncertainty begins to subside.
Stock Price
On Wednesday, Natera Inc. (NATERA) stock opened at $47.1 and closed at $47.1—unchanged from its previous closing price of $47.1. Although Natera’s financials have been mostly positive with revenue increasing significantly over the last few quarters, the company’s market growth has stalled due to the biomedical industry’s stiff competition and unforeseen macroeconomic factors. Nevertheless, investors remain optimistic about Natera’s long-term prospects given their strong product portfolio and partnerships with other firms, such as Illumina and Quest Diagnostics. As such, although Piper Sandler lowered its price target for NATERA, it maintained an overweight rating for the stock, indicating that there is still potential for investors to benefit from their investments in Natera in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 867.85 | -546.14 | -62.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -375.11 | 138.96 | 480.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.32k | 668.31 | 5.74 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 38.1% | – | -61.6% |
| FCF Margin | ROE | ROA |
| -48.2% | -49.3% | -25.3% |
Analysis
At GoodWhale, we conducted an in-depth analysis of NATERA’s wellbeing. After looking at a number of financial and business aspects, we concluded that NATERA is a high risk investment. To back this up, we identified four risk warnings across balance sheet, cashflow statement, non-financial and financial journal. We encourage you to register on GoodWhale.com to check out these warnings and make an informed decision. More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
The analysts believe that Natera‘s long-term potential remains strong, but its short-term outlook is uncertain due to the economic uncertainty. Investors should remain cautious when investing in Natera and monitor the company’s progress during these turbulent times.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
